Try Ask OE! Our NEW Advanced AI Enabled Search
Dive into the Largest Database of
Musculoskeletal Evidence
ACE Reports.
Make a selection below to explore our full database of 3 results matching: "FT Murphy"
ACE Reports
(3 Reports)
ACE Reports
Our AI driven High Impact metric predicts an article's future number of citations by considering the content of the article.
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Open Advanced Search
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Osteoarthritis
Tanezumab Reduces Osteoarthritic Hip Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial
Arthritis Rheum. 2013 Jul;65(7):1795-803. doi: 10.1002/art.37950
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Tanezumab Reduces Osteoarthritic Hip Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial
Arthritis Rheum. 2013 Jul;65(7):1795-803. doi: 10.1002/art.37950
General Orthopaedics
Tanezumab Reduces Osteoarthritic Knee Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial
J Pain. 2012 Aug;13(8):790-8. doi: 10.1016/j.jpain.2012.05.006. Epub 2012 Jul 10.
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Tanezumab Reduces Osteoarthritic Knee Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial
J Pain. 2012 Aug;13(8):790-8. doi: 10.1016/j.jpain.2012.05.006. Epub 2012 Jul 10.
General Orthopaedics
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial
Lancet. 2009 Jul 18;374(9685):210-21. Epub 2009 Jun 26
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial
This report has been verified by one or more authors of the original publication.
Lancet. 2009 Jul 18;374(9685):210-21. Epub 2009 Jun 26